Biologic therapy persistence in psoriatic arthritis often depends on whether the drug was a first or second treatment, with depression, anxiety, older age and higher tender joint count also leading to discontinuation, according to data.
“The development of new biological disease-modifying antirheumatic drugs (bDMARDs) for PsA has led to better disease control as well as slowing of radiographic progression,” Mohamad-Ali Rida, MD, of the Center for Prognosis Studies at Toronto Western Hospital, in Canada, and colleagues wrote in Arthritis Care & Research. “Once an advanced